SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Amgen Inc. (AMGN)
An SI Board Since December 1996
Posts SubjectMarks Bans Symbol
1906 112 0 AMGN
Emcee:  trevor john wilkinson Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
31 Stephen, i would be appreciative of the posting of the DS recommendation. i amEepOpp-2/19/1997
30 Does anyone have information or news on Amgen's recently cloned gene, TP1? Renee-2/19/1997
29 AMGN is $59 1/4 this morning. I have LEAPS expiring Jan 1998. Do you have anyYani Strei-2/18/1997
28 I went long on AMGN today on the weakness @ 55-5/8 which is nearly 16% off its Stephen Bedingfield-2/12/1997
27 Some of Amgen's best items have been their cytokines. These are chemicals jchopper-2/11/1997
26 My broker advised me on Friday that an American analyst had just recommended AMStephen Bedingfield-2/8/1997
25 I hear that there is a new issue from some of the people originally involved inT. Pascal-2/4/1997
24 In short: high risk, and don't like, won't buy .Barron Von Hymen-1/30/1997
23 hello Barron, i am curious. with all those pharmaceuticals and biotechs that yEepOpp-1/30/1997
22 Hi Tom, I own a little Amgen as long-term position. It's the biggest biotePhilip H. Lee-1/20/1997
21 My biotech custom portfolio for interest only: Amgen Oncogene Ligand Nexstar GBarron Von Hymen-1/20/1997
20 Philip, it has been a while since we last chatted. Guess what---I am thinking Tom Trader-1/18/1997
19 Expected earnings release date for AMGN: 1/29. Consensus estimate = 0.69. SourPhilip H. Lee-1/17/1997
18 Infergen, for hepatitis, may launch this year, with market potential about 100 Steve Sakson-1/17/1997
17 Does anyone have an understanding of the company's new drug pipeline. I heaVector1-1/16/1997
16 AMGN upped to Rec. List-Buy from Buy At Donaldson, Lufkin, Jenrette (DLJ) citinWallace Rivers-1/14/1997
15 HOT TIP (for everyone) Check out AUSPEX (ASPX) It's the best stock out tJeff-1/14/1997
14 I guess I can respond to myself. Brian, you were wrong on both counts. 1. Meridian-1/13/1997
13 AMGN had its ratings cut by a number of analysts since it reported that bdnf Vector1-1/13/1997
12 Lana, Amgen was down because the REGN trial was released and the data were notMeridian-1/12/1997
11 Regeneron is Amgen's partner in BDNF for Lou Gehrig's Disease. For morThe Thrifty Investor-1/12/1997
10 Yes, I would regard the pullback as an opportunity to purchase more. Any biotecThe Thrifty Investor-1/12/1997
9 The reason that Amgen was down on Friday is that the phase III trials for BDNF,The Thrifty Investor-1/12/1997
8 Thank you for the idea. I may try it. Regarding the 2 3/4 AMGN was down FridaLana M. Hinton-1/11/1997
7 I have been long on AMGN for 1 1/2 years. I have been wishing I had purcased mDick-1/10/1997
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News